Your session is about to expire
← Back to Search
Anti-viral agent
Amantadine for Long COVID
Phase 2
Recruiting
Led By Amy Mathews, M.D.
Research Sponsored by University of Texas Southwestern Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age 20-65
Endorse symptoms during their initial evaluation and history with the provider that began around the time of the acute COVID19 infection (subjective) including cognitive changes such as cognitive fatigue, brain fog, memory issues, attention issues AND have symptoms in at least 1 out of the 2 following symptom categories: Category 1: Decreased endurance, physical fatigue, weakness Category 2: Depression, anxiety
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4-6 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to test if using amantadine can help reduce symptoms, improve thinking abilities, increase endurance, and reduce fatigue in people with long-lasting symptoms of COVID-19. If amant
Who is the study for?
This trial is for English-speaking adults aged 20-65 who had a confirmed COVID-19 test result between 8 weeks and one year before the initial visit. It's aimed at those experiencing long-COVID symptoms like decreased endurance, fatigue, weakness, depression, or anxiety.
What is being tested?
The study tests whether Amantadine can help reduce symptoms and improve cognitive function and endurance in 'long-hauler' COVID patients. Participants will also receive counseling and may engage in physical, occupational, or speech therapy as part of their treatment.
What are the potential side effects?
While not specified here, common side effects of Amantadine may include dizziness, dry mouth, difficulty concentrating or sleeping; however individual experiences with side effects can vary.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 20 and 65 years old.
Select...
I have experienced cognitive issues and either physical fatigue or mental health problems since having COVID-19.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 4-6 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4-6 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Measures of cognitive functioning
Secondary study objectives
Measures of anxiety and depression
Measures of endurance and strength
Measures of fatigue
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Standard of Care + AmantadineExperimental Treatment4 Interventions
Participants in this arm will review standard of care and amantadine.
Group II: Standard of CareActive Control3 Interventions
Participants in this arm will receive current standard of care for PASC symptoms which may include: PT, OT, SLP, provider counseling, and/or pharmacologic interventions for targeted symptom management.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Amantadine
2010
Completed Phase 4
~780
Find a Location
Who is running the clinical trial?
University of Texas Southwestern Medical CenterLead Sponsor
1,089 Previous Clinical Trials
1,059,653 Total Patients Enrolled
Amy Mathews, M.D.Principal InvestigatorUT Southwestern Medical Center